2025年《中华人民共和国民营经济促进法》出台，南京也将激发民企动力和潜能作为重中之重， 制定《南京市民营经济高质量发展2025年工作要点》《关于落实促进我市民营企业发展若干工作举措 的通知》等政策文件，为民营企业发展保驾护航。 乘政策长风，在过去的一年，南京民营企业在空白地带"插旗立标"，凭硬核技术"开疆拓土"，向产 业高峰"攀登不止"。让我们从跃动的数字里，聆听民企拔节生长的声音，触摸南京经济的强劲脉搏。 在经济发展的浩瀚海洋，民营企业始终是破浪前行的活力与希望。 扛起科技创新大旗，南京"黑科技"闪耀春晚舞台 【滚烫数据】 去年，我市共推荐5351家企业申报高新技术企业，民企占比超90%；2025年市级重大科技专项共 67项，民企占比同样超过90%；"宁科贷"累计发放科技贷款超2700亿元，金融"活水"精准滴灌。全市民 营企业创新能力显著提升，一批关键核心技术取得突破，为产业升级注入强大动能。 【火热实践】 在2026年央视春晚小品《奶奶的最爱》中，来自松延动力的人形机器人吸睛无数。这些机器人的 关节模组来自南京因克斯智能科技有限公司，而这家成立于2022年的年轻公司，并非首次"出圈"。在去 年4月举办的 ...

Group 1 - The core point of the article is that the first patient has successfully received treatment with the drug Opalizumab (LBL-024) in a Phase Ib/II clinical trial for recurrent or metastatic triple-negative breast cancer (TNBC) [1] - The clinical trial is an open-label, multi-center study led by Professor Yin Yongmei from Jiangsu Provincial People's Hospital, aiming to evaluate the efficacy and safety of Opalizumab alone or in combination with albumin-bound paclitaxel for TNBC patients [1] - The drug Opalizumab is a bispecific antibody targeting both PD-L1 and 4-1BB, and it is the first targeted therapy for the 4-1BB receptor to reach the registration clinical stage for extra-pulmonary neuroendocrine carcinoma [2] Group 2 - In two clinical trials in China, Opalizumab has shown encouraging efficacy signals and good safety profiles, whether used as a monotherapy or in combination with chemotherapy for advanced extra-pulmonary neuroendocrine carcinoma [3] - The company received approval from the National Medical Products Administration (NMPA) in April 2024 to conduct a single-arm registration clinical trial and obtained breakthrough therapy designation (BTD) in October 2024 for treating advanced extra-pulmonary neuroendocrine carcinoma [3] - Cancer is a leading cause of morbidity and mortality globally, with breast cancer being the second most common cancer after lung cancer, and TNBC represents a subtype with high malignancy and poor prognosis, accounting for about 15% to 20% of all breast cancer cases [4]